Fungal sensitization in patients with severe atopic dermatitis as a distinct phenotype
- Authors: Fomina D.S.1,2, Lebedkina M.S.2, Chernov A.A.2,3, Nikitina E.A.1, Mukhina O.A.2, Mikhaylova V.I.2
-
Affiliations:
- Sechenov First Moscow State Medical University (Sechenov University)
- City Clinical Hospital №52
- Russian Medical Academy of Continuous Professional Education
- Issue: Vol 24, No 8 (2022)
- Pages: 552-557
- Section: Articles
- URL: https://journals.rcsi.science/2075-1753/article/view/112312
- DOI: https://doi.org/10.26442/20751753.2022.8.201908
- ID: 112312
Cite item
Full Text
Abstract
Background. Many factors influence the development of atopic dermatitis (AD): genetic, environmental (including exposure to allergens), skin barrier damage, and activation of the T2-pathway immune response. Patients with AD, including those with severe disease, are prone to sensitization to various allergens, including fungal ones. Fungal sensitization (FS) promotes autoreactivity to the body's own structures due to shared epitopes with homologous fungal allergens. It can contribute to the development of allergic diseases, including AD, asthma, and rhinitis, as well as to their exacerbation and uncontrolled course. Since FS can be considered a factor aggravating AD, it is relevant to distinguish patients with FS and AD into a separate phenotype.
Aim. To characterize the phenotype of patients with severe AD and FS using retrospective data analysis from a digital analytics platform in a real-world clinical setting.
Materials and methods. A retrospective observational single-center study was conducted between 01.06.2017 and 01.07.2022. The study cohort included 88 patients with severe AD who were candidates for therapy or received treatment with either dupilumab or upadacitinib. FS was confirmed in 49 patients from the study group. Part of the cohort without FS (n=39) was used as a comparison group. Inclusion criteria: the age over 18 years old; severe AD (SCORAD>40 points at the beginning of therapy); determination of specific immunoglobulin E to a panel of fungal allergens or individual fungi (or by the ImmunoCAP ISAC method to fungal allergen components). A digital analytics platform was used to generate primary data.
Results. The phenotype of a patient with severe AD and confirmed FS was described. The patient profile is characterized by an extended sensitization spectrum (at least 3–4 allergen groups) with the most typical combination of pollen, epidermal, and FS. If there is a food allergy, it is of the classic "big eight" nature. Besides exacerbation of the skin disorder, its manifestations include angioedema of life-threatening localization and bronchospasm. Markers of T2 inflammation (high levels of immunoglobulin E and blood eosinophilia) are observed according to the test results, and the T2 endotype of allergy-related abnormalities is typical.
Conclusion. Apparently, the presence of FS in patients with AD may exacerbate parenteral sensitization mechanisms, expanding its spectrum, including food allergens. Therefore, distinguishing the phenotype of severe AD with FS needs further detailing with a subsequent adaptation of monitoring and treatment methods of severe AD.
Full Text
##article.viewOnOriginalSite##About the authors
Daria S. Fomina
Sechenov First Moscow State Medical University (Sechenov University); City Clinical Hospital №52
Email: daria_fomina@mail.ru
ORCID iD: 0000-0002-5083-6637
Cand. Sci. (Med.)
Russian Federation, Moscow; MoscowMarina S. Lebedkina
City Clinical Hospital №52
Email: mari-na.ivanova0808@yandex.ru
ORCID iD: 0000-0002-9545-4720
allergist-immunologist
Russian Federation, MoscowAnton A. Chernov
City Clinical Hospital №52; Russian Medical Academy of Continuous Professional Education
Author for correspondence.
Email: sbornay1med@yandex.ru
ORCID iD: 0000-0001-6209-387X
therapist
Russian Federation, Moscow; MoscowEkaterina A. Nikitina
Sechenov First Moscow State Medical University (Sechenov University)
Email: katrin88866@gmail.com
ORCID iD: 0000-0002-0865-8355
Clinical Resident
Russian Federation, MoscowOlga A. Mukhina
City Clinical Hospital №52
Email: mukhina.a.o@gmail.com
ORCID iD: 0000-0002-3794-4991
allergist-immunologist
Russian Federation, MoscowValeriya I. Mikhaylova
City Clinical Hospital №52
Email: lera1208@list.ru
ORCID iD: 0000-0003-0921-9212
SPIN-code: 2841-9652
allergist-immunologist
Russian Federation, MoscowReferences
- Атопический дерматит. Проект клинических рекомендаций. 2020 г. РААКИ. Режим доступа: https://raaci.ru/dat/pdf/KR/atopic_dermatitis_2020.pdf. Ссылка активна на 05.09.2022 [Atopic dermatitis. Draft clinical guidelines. 2020 RAAKI. Available at: https://raaci.ru/dat/pdf/KR/atopic_dermatitis_2020.pdf. Accessed: 05.09.2022 (in Russian)].
- Kvenshagen B, Jacobsen M, Halvorsen R. Atopic Dermatitis in Premature and Term Children. Arch Dis Child. 2009;94(3):202-5. doi: 10.1136/adc.2008.142869
- Esaki H, Brunner PM, Renert-Yuval Y, et al. Early-onset pediatric atopic dermatitis is TH2 but also TH17 polarized in skin. J Allergy Clin Immunol. 2016;138(6):1639-51. doi: 10.1016/j.jaci.2016.07.013
- Фомина Д.С., Сердотецкова С.А., Чернов А.А., и др. Оптимизация подходов к ведению взрослых пациентов с тяжелым атопическим дерматитом: анализ результатов реальной клинической практики. Consilium Medicum. 2021;23(8):654-61 [Fomina DS, Serdotetskova SA, Chernov AA, et al. Optimization of approaches to the management of adult patients with severe atopic dermatitis: analysis of real clinical practice outcomes. Consilium Medicum. 2021;23(8):654-61 (in Russian)]. doi: 10.26442/20751753.2021.8.201115
- Fukutomi Y, Taniguchi M. Sensitization to fungal allergens: Resolved and unresolved issues. Allergol Int. 2015;64(4):321-31. doi: 10.1016/j.alit.2015.05.007; PMID: 26433528
- Goleva E, Calatroni A, LeBeau P, et al. Skin tape proteomics identifies pathways associated with transepidermal water loss and allergen polysensitization in atopic dermatitis. J Allergy Clin Immunol. 2020;146(6):1367-78. doi: 10.1016/j.jaci.2020.04.022; PMID: 32360271; PMCID: PMC7606732
- Simon-Nobbe B, Denk U, Pöll V, et al. The spectrum of fungal allergy. Int Arch Allergy Immunol. 2008;145(1):58-86. doi: 10.1159/000107578; PMID: 17709917
- Jakšić Despot D, Segvić Klarić M. A year-round investigation of indoor airborne fungi in Croatia. Arh Hig Rada Toksikol. 2014;65(2):209-18. doi: 10.2478/10004-1254-65-2014-2483; PMID: 24846954
- Crameri R, Weichel M, Flückiger S, et al. Fungal allergies: a yet unsolved problem. Chem Immunol Allergy. 2006;91:121-33. doi: 10.1159/000090276
- Yang G, Seok JK, Kang HC, et al. Skin Barrier Abnormalities and Immune Dysfunction in Atopic Dermatitis. Int J Mol Sci. 2020;21(8):2867. doi: 10.3390/ijms21082867; PMID: 32326002; PMCID: PMC7215310
- Simon D, Kernland Lang K. Atopic dermatitis: from new pathogenic insights toward a barrier-restoring and anti-inflammatory therapy. Curr Opin Pediatr. 2011;23(6):647-52. doi: 10.1097/MOP.0b013e32834cad0a; PMID: 21970829
- Silverberg JI, Gelfand JM, Margolis DJ, et al. Patient burden and quality of life in atopic dermatitis in US adults: A population-based cross-sectional study. Ann Allergy Asthma Immunol. 2018;121(3):340-7. doi: 10.1016/j.anai.2018.07.006; PMID: 30025911
- Patel KR, Immaneni S, Singam V, et al. Association Between Atopic Dermatitis, Depression, and Suicidal Ideation: A Systematic Review and Meta-Analysis. J Am Acad Dermatol. 2019;80(2):402-10. doi: 10.1016/j.jaad.2018.08.063
- Seegräber M, Srour J, Walter A, et al. Dupilumab for treatment of atopic dermatitis. Expert Rev Clin Pharmacol. 2018;11(5):467-74. doi: 10.1080/17512433.2018.1449642; PMID: 29557246
- Guttman-Yassky E, Thaçi D, Pangan AL, et al. Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial. J Allergy Clin Immunol. 2020;145(3):877-84. doi: 10.1016/j.jaci.2019.11.025; PMID: 31786154
- Domínguez O, Plaza AM, Alvaro M. Relationship Between Atopic Dermatitis and Food Allergy. Curr Pediatr Rev. 2020;16(2):115-22. doi: 10.2174/1573396315666191111122436; PMID: 31713486
- Graham F, Eigenmann PA. Atopic dermatitis and its relation to food allergy. Curr Opin Allergy Clin Immunol. 2020;20(3):305-10. doi: 10.1097/ACI.0000000000000638; PMID: 32109909
- Hallen-Adams HE, Suhr MJ. Fungi in the healthy human gastrointestinal tract. Virulence. 2017;8(3):352-8. doi: 10.1080/21505594.2016.1247140; PMID: 27736307; PMCID: PMC5411236
- Kapitan M, Niemiec MJ, Steimle A, et al. Fungi as Part of the Microbiota and Interactions with Intestinal Bacteria. Curr Top Microbiol Immunol. 2019;422:265-301. doi: 10.1007/82_2018_117; PMID: 30062595
- Baker JL, Bor B, Agnello M, et al. Ecology of the Oral Microbiome: Beyond Bacteria. Trends Microbiol. 2017;25(5):362-74. doi: 10.1016/j.tim.2016.12.012; PMID: 28089325; PMCID: PMC5687246
- Egert M, Simmering R, Riedel CU. The Association of the Skin Microbiota With Health, Immunity, and Disease. Clin Pharmacol Ther. 2017;102(1):62-9. doi: 10.1002/cpt.698; PMID: 28380682
- Han SH, Cheon HI, Hur MS, et al. Analysis of the skin mycobiome in adult patients with atopic dermatitis. Exp Dermatol. 2018;27:366-73.
- Paulino LC, Tseng CH, Strober BE, Blaser MJ. Molecular analysis of fungal microbiota in samples from healthy human skin and psoriatic lesions. J Clin Microbiol. 2006;44(8):2933-41. doi: 10.1128/JCM.00785-06; PMID: 16891514; PMCID: PMC1594634
- Warren CM, Jiang J, Gupta RS. Epidemiology and Burden of Food Allergy. Curr Allergy Asthma Rep. 2020;20(2):6. doi: 10.1007/s11882-020-0898-7; PMID: 32067114; PMCID: PMC7883751
- Manam S, Tsakok T, Till S, Flohr C. The association between atopic dermatitis and food allergy in adults. Curr Opin Allergy Clin Immunol. 2014;14(5):423-9. doi: 10.1097/ACI.0000000000000095; PMID: 25153338
- Celakovská J, Josef B, Ettler K, et al. Sensitization to Fungi in Atopic Dermatitis Patients 14 Year and Older – Association with Other Atopic Diseases and Parameters. Indian J Dermatol. 2018;63(5):391-8. doi: 10.4103/ijd.IJD_493_17; PMID: 30210160; PMCID: PMC6124231
- Zhang E, Tanaka T, Tajima M, et al. Characterization of the skin fungal microbiota in patients with atopic dermatitis and in healthy subjects. Microbiol Immunol. 2011;55:625-32.
- Byrd AL, Belkaid Y, Segre JA. The human skin microbiome. Nat Rev Microbiol. 2018;16(3):143-55. doi: 10.1038/nrmicro.2017.157; PMID: 29332945
- Nezamololama N, Fieldhouse K, Metzger K, Gooderham M. Emerging systemic JAK inhibitors in the treatment of atopic dermatitis: a review of abrocitinib, baricitinib, and upadacitinib. Drugs Context. 2020;9:2020-8-5. doi: 10.7573/dic.2020-8-5; PMID: 33240390; PMCID: PMC7673622
- Iweala OI, Choudhary SK, Commins SP. Food Allergy. Curr Gastroenterol Rep. 2018;20(5):17. doi: 10.1007/s11894-018-0624-y; PMID: 29623490; PMCID: PMC5940350
- Lack G. Epidemiologic risks for food allergy. J Allergy Clin Immunol. 2008;121(6):1331-6. doi: 10.1016/j.jaci.2008.04.032; PMID: 18539191
- Celakovska J, Vankova R, Bukac J, et al. Atopic Dermatitis and Sensitisation to Molecular Components of Alternaria, Cladosporium, Penicillium, Aspergillus, and Malassezia-Results of Allergy Explorer ALEX 2. J Fungi (Basel). 2021;7(3):183. doi: 10.3390/jof7030183; PMID: 33806376; PMCID: PMC8001933